The company said revenue for the 3-month period ended June 30, 2024 rose 9% from the same period a year earlier to $1,223.2 million (vs. $1,122.1 million a year earlier), and income from operations rose 38% to $381.2 million.

1. 01

   The company said revenue for the 3-month period ended June 30, 2024 rose 9% from the same period a year earlier to $1,223.2 million (vs. $1,122.1 million a year earlier), and income from operations rose 38% to $381.2 million.

2. 02

   ResMed said its gross margin for Q4 improved to 58.5%, up 350 basis points, and cited reduced freight and manufacturing cost improvements, higher average selling prices and favorable product mix as the main factors.

3. 03

   ResMed said revenue for fiscal 2024 (the 12-month period ended June 30, 2024) rose 11% to $4,685.3 million, with net income of $1,021.0 million, diluted earnings per share of $6.92 and operating cash flow of $1,401,260 thousand.

4. 04

   ResMed said its board declared a quarterly cash dividend of $0.53 per share, with a record date of August 15, 2024 and a payment date of September 19, 2024. The company said it paid dividends of $71 million in Q4 and repurchased 232,000 shares for $50 million.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.